Open Access

Endostatin improves cancer-associated systemic syndrome in a lung cancer model

  • Authors:
    • Xia Wang
    • Rui‑Yu Zhan
    • Yu‑Yi Wang
    • Xi Yan
    • Dan Cao
    • Yan Li
    • Yi‑Qin Wang
    • Feng Luo
  • View Affiliations

  • Published online on: March 17, 2015     https://doi.org/10.3892/ol.2015.3049
  • Pages: 2023-2030
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cancer-associated systemic syndrome (CASS) is characterized by a constellation of symptoms, including progressive weight loss, anemia, endocrine disorders, gastrointestinal dysfunction, muscle and adipose atrophy, hepatic peliosis and kidney failure. The present study assesses the effects of endostatin on CASS and any possible underlying mechanism in tumor‑bearing mice. The results showed that the inoculation of Lewis lung carcinoma cells into mice led to CASS that was characterized by a notable decrease in body weight, severe anemia phenotype, disordered biochemistry, hepatosplenomegaly, and a marked increase in serum vascular endothelial growth factor (VEGF), tumor necrosis factor α and interleukin‑6 (IL‑6). The continuous injection of 10 mg/kg/day endostatin suppressed tumor growth and alleviated CASS in the tumor‑bearing mice, as shown by weight gain, improvement in biochemistry and anemia, and the preservation of organ function. The effects of endostatin on CASS in the tumor‑bearing mice were accompanied by the downregulation of serum VEGF and IL‑6. Collectively, these findings indicate that endostatin improves CASS in tumor‑bearing mice by decreasing the serum levels of VEGF and IL-6.
View Figures
View References

Related Articles

Journal Cover

May-2015
Volume 9 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang X, Zhan RY, Wang YY, Yan X, Cao D, Li Y, Wang YQ and Luo F: Endostatin improves cancer-associated systemic syndrome in a lung cancer model. Oncol Lett 9: 2023-2030, 2015.
APA
Wang, X., Zhan, R., Wang, Y., Yan, X., Cao, D., Li, Y. ... Luo, F. (2015). Endostatin improves cancer-associated systemic syndrome in a lung cancer model. Oncology Letters, 9, 2023-2030. https://doi.org/10.3892/ol.2015.3049
MLA
Wang, X., Zhan, R., Wang, Y., Yan, X., Cao, D., Li, Y., Wang, Y., Luo, F."Endostatin improves cancer-associated systemic syndrome in a lung cancer model". Oncology Letters 9.5 (2015): 2023-2030.
Chicago
Wang, X., Zhan, R., Wang, Y., Yan, X., Cao, D., Li, Y., Wang, Y., Luo, F."Endostatin improves cancer-associated systemic syndrome in a lung cancer model". Oncology Letters 9, no. 5 (2015): 2023-2030. https://doi.org/10.3892/ol.2015.3049